Sotorasib versus docetaxel for previously treated KRAS G12C–mutated non–small–cell lung cancer: a plain language summary

Plain Language Summary: What is this summary about? The CodeBreaK 200 clinical study included patients with a type of lung cancer called non–small-cell lung cancer that has spread outside the lung (advanced) and had a particular change (mutation) in the KRAS gene. This mutation leads to the mutated protein called KRAS G12C and can lead to lung cancer. The CodeBreaK 200 clinical study looked at whether treatment with sotorasib works better and has fewer side effects than docetaxel. Sotorasib has accelerated approval or full approval for use in over 50 countries for patients with previouslytreated advanced KRAS G12C–mutated non–small-cell lung cancer. What did investigators find? There were 171 adults in the sotorasib group and 174 in the docetaxel group. The median time that patients in the sotorasib group whose disease was no worse or who did not die was 5.6 months. For patients in the docetaxel group, this was 4.5 months. After 1 year, 25% of patients in the sotorasib group had disease that was no worse or did not die. This happened in 100% of patients in the docetaxel group. In total, 48 out of 171 patients (28%) in the sotorasib group had a positive effect to treatment, and their tumors shrunk in size by at least 30% or disappeared. This happened in 23 out of 174 patients (13%) in the docetaxel group. Additionally, 141 out of 171 patients (82%) in the sotorasib group had tumors that either remained stable or shrunk in size. This happened in 105 out of 174 patients (60%) in the docetaxel group. Patients in both the sotorasib and docetaxel groups had a similar median survival (10.6 months in the sotorasib group compared with 11.3 months in the docetaxel group). Almost all patients treated with sotorasib or docetaxel had side effects. They were severe in 56 out of 169 patients (33%) receiving sotorasib and 61 out of 151 patients (40%) receiving docetaxel. What is the key takeaway? Sotorasib is an effective treatment for previously–treated patients with advanced KRAS G12C–mutated non–small-cell lung cancer. This is an abstract of the Plain Language Summary of Publication article. View the full Plain Language Summary PDF of this article to read the full-text.

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2025-03-24
DOI
https://doi.org/10.1080/14796694.2025.2474789
Citations
2
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
3.04

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Sotorasib versus docetaxel for previously treated KRAS G12C–mutated non–small–cell lung cancer: a plain language summary

Helena Linardou, Yasuto Yoneshima, Anthonie J. van der Wekken, Bhakti Mehta et al.
2 citations
Future Oncology
Lung Cancer Treatments and Mutations
3.04
article

Sotorasib versus docetaxel for previously treated KRAS G12C–mutated non–small–cell lung cancer: a plain language summary

Helena Linardou, Yasuto Yoneshima, Anthonie J. van der Wekken, Bhakti Mehta, Anne‐Marie C. Dingemans, Normand Blais, Colin R. Lindsay, Christophe Dooms, Martin Schüler, H. Léna, Giannis Mountzios, Benjamin Solomon, Sang‐We Kim, Björn Stollenwerk, Ferdinandos Skoulidis, Melissa L. Johnson, Cynthia C. Obiozor, Luis Paz‐Ares, David Michael Waterhouse, Julien Mazières, Adrianus J. de Langen, Solange Peters, Yuanbin Chen, Carlos Gil Ferreira, Tracy Varrieur, Suresh S. Ramalingam, Enriqueta Felip, Miklos Pless, Silvia Novello, Jürgen Wolf, Gataree Ngarmchamnanrith, Yang Wang
article en
2 citations

Abstract

Plain Language Summary: What is this summary about? The CodeBreaK 200 clinical study included patients with a type of lung cancer called non–small-cell lung cancer that has spread outside the lung (advanced) and had a particular change (mutation) in the KRAS gene. This mutation leads to the mutated protein called KRAS G12C and can lead to lung cancer. The CodeBreaK 200 clinical study looked at whether treatment with sotorasib works better and has fewer side effects than docetaxel. Sotorasib has accelerated approval or full approval for use in over 50 countries for patients with previouslytreated advanced KRAS G12C–mutated non–small-cell lung cancer. What did investigators find? There were 171 adults in the sotorasib group and 174 in the docetaxel group. The median time that patients in the sotorasib group whose disease was no worse or who did not die was 5.6 months. For patients in the docetaxel group, this was 4.5 months. After 1 year, 25% of patients in the sotorasib group had disease that was no worse or did not die. This happened in 100% of patients in the docetaxel group. In total, 48 out of 171 patients (28%) in the sotorasib group had a positive effect to treatment, and their tumors shrunk in size by at least 30% or disappeared. This happened in 23 out of 174 patients (13%) in the docetaxel group. Additionally, 141 out of 171 patients (82%) in the sotorasib group had tumors that either remained stable or shrunk in size. This happened in 105 out of 174 patients (60%) in the docetaxel group. Patients in both the sotorasib and docetaxel groups had a similar median survival (10.6 months in the sotorasib group compared with 11.3 months in the docetaxel group). Almost all patients treated with sotorasib or docetaxel had side effects. They were severe in 56 out of 169 patients (33%) receiving sotorasib and 61 out of 151 patients (40%) receiving docetaxel. What is the key takeaway? Sotorasib is an effective treatment for previously–treated patients with advanced KRAS G12C–mutated non–small-cell lung cancer. This is an abstract of the Plain Language Summary of Publication article. View the full Plain Language Summary PDF of this article to read the full-text.

Future OncologyVol. 21(9)
Ulsan College (KR), University Medical Center Groningen (NL), The University of Texas MD Anderson Cancer Center (US), Emory University (US), University of Groningen (NL), Peter MacCallum Cancer Centre (AU), Asan Medical Center (KR), University of Manchester (GB), The Netherlands Cancer Institute (NL), Centre Hospitalier Universitaire de Toulouse (FR), University of Ulsan (KR), Fukuoka University Hospital (JP), Kyushu University Hospital (JP), Electronic Sensor Technology (United States) (US), Kantonsspital Winterthur (CH), Sarah Cannon (US), Hospital Universitario 12 De Octubre (ES), Vall d'Hebron Hospital Universitari (ES), Cancer Research UK Manchester Institute (GB), The Christie NHS Foundation Trust (GB), Tennessee Oncology (US), Amgen (Switzerland) (CH), Centre Hospitalier de l’Université de Montréal (CA), Erasmus MC Cancer Institute (NL), Metropolitan Hospital (GR), Hematology Oncology Consultants (US), University Hospital Cologne (DE), Henry Dunant Hospital (GR), Oncology Hematology Care (US), Centre Hospitalier Universitaire de Rennes (FR), Ospedale San Luigi Gonzaga (IT), University of Lausanne (CH), KU Leuven (BE)
Amgen
Openalex Percentile: Top 10%
Lung Cancer Treatments and Mutations
3.04
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.